Acoustic neuroma screening: Difference between revisions
| Line 5: | Line 5: | ||
According to the U.S. Preventive Services Task Force (USPTF), screening for [[acoustic neuroma]] is not recommended. Evaluation for [[Neurofibromatosis type II|NF-2]] should be done in individuals with an apparently sporadic [[Acoustic neuroma|vestibular schwannoma]] occurring at less than 30 years of age, or a [[spinal tumor]] or [[meningioma]] occurring at less than 20 years of age. | According to the U.S. Preventive Services Task Force (USPTF), screening for [[acoustic neuroma]] is not recommended. Evaluation for [[Neurofibromatosis type II|NF-2]] should be done in individuals with an apparently sporadic [[Acoustic neuroma|vestibular schwannoma]] occurring at less than 30 years of age, or a [[spinal tumor]] or [[meningioma]] occurring at less than 20 years of age. | ||
==Screening== | ==Screening== | ||
According to U.S. Preventive Services Task Force (USPTF), [[Screening (medicine)|screening]] for acoustic neuroma is not recommended. Annual hearing screening with BAER (Brain stem auditory evoked response test), with referral to an audiologist for amplification, or speech therapy is recommended in patients with [[Neurofibromatosis type II|NF-2]]. Evaluation for NF-2 should be done in individuals with an apparently sporadic vestibular schwannoma occurring at less than 30 years of age, or a spinal tumor or meningioma occurring at less than 20 years of age.<ref name="pmid17470137">{{cite journal| author=Evans DG, Ramsden RT, Gokhale C, Bowers N, Huson SM, Wallace A| title=Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? | journal=Clin Genet | year= 2007 | volume= 71 | issue= 4 | pages= 354-8 | pmid=17470137 | doi=10.1111/j.1399-0004.2007.00778.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17470137 }} </ref> | According to U.S. Preventive Services Task Force (USPTF), [[Screening (medicine)|screening]] for acoustic neuroma is not recommended. Annual hearing screening with BAER (Brain stem auditory evoked response test), with referral to an audiologist for amplification, or speech therapy is recommended in patients with [[Neurofibromatosis type II|NF-2]]. Evaluation for NF-2 should be done in individuals with an apparently sporadic vestibular schwannoma occurring at less than 30 years of age, or a spinal tumor or meningioma occurring at less than 20 years of age.<ref name="pmid17470137">{{cite journal| author=Evans DG, Ramsden RT, Gokhale C, Bowers N, Huson SM, Wallace A| title=Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? | journal=Clin Genet | year= 2007 | volume= 71 | issue= 4 | pages= 354-8 | pmid=17470137 | doi=10.1111/j.1399-0004.2007.00778.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17470137 }} </ref><ref>{{Cite journal | ||
| author = [[D. Gareth R. Evans]] | |||
| title = Neurofibromatosis type 2 (NF2): a clinical and molecular review | |||
| journal = [[Orphanet journal of rare diseases]] | |||
| volume = 4 | |||
| pages = 16 | |||
| year = 2009 | |||
| month = June | |||
| doi = 10.1186/1750-1172-4-16 | |||
| pmid = 19545378 | |||
}}</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 17:39, 19 December 2018
|
Acoustic neuroma Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Acoustic neuroma screening On the Web | |
|
American Roentgen Ray Society Images of Acoustic neuroma screening | |
|
Risk calculators and risk factors for Acoustic neuroma screening | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2] Mohsen Basiri M.D.
Overview
According to the U.S. Preventive Services Task Force (USPTF), screening for acoustic neuroma is not recommended. Evaluation for NF-2 should be done in individuals with an apparently sporadic vestibular schwannoma occurring at less than 30 years of age, or a spinal tumor or meningioma occurring at less than 20 years of age.
Screening
According to U.S. Preventive Services Task Force (USPTF), screening for acoustic neuroma is not recommended. Annual hearing screening with BAER (Brain stem auditory evoked response test), with referral to an audiologist for amplification, or speech therapy is recommended in patients with NF-2. Evaluation for NF-2 should be done in individuals with an apparently sporadic vestibular schwannoma occurring at less than 30 years of age, or a spinal tumor or meningioma occurring at less than 20 years of age.[1][2]
References
- ↑ Evans DG, Ramsden RT, Gokhale C, Bowers N, Huson SM, Wallace A (2007). "Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?". Clin Genet. 71 (4): 354–8. doi:10.1111/j.1399-0004.2007.00778.x. PMID 17470137.
- ↑ D. Gareth R. Evans (2009). "Neurofibromatosis type 2 (NF2): a clinical and molecular review". Orphanet journal of rare diseases. 4: 16. doi:10.1186/1750-1172-4-16. PMID 19545378. Unknown parameter
|month=ignored (help)